[ENTA] Enanta Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 34.53 Change: 1.51 (4.57%)
Ext. hours: Change: 0 (0%)

chart ENTA

Refresh chart

Strongest Trends Summary For ENTA

ENTA is in the medium-term down -12% below S&P in 4 months. In the long-term up 274% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 36.42% Sales Growth - Q/Q-25.98% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA47.08% ROE51.63% ROI
Current Ratio8.98 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin82.62% Net Profit Margin64.48% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.26 M Cash From Investing Activities-100.46 M Cash From Operating Activities93.25 M Gross Profit
Net Profit28.75 M Operating Profit48.56 M Total Assets245.88 M Total Current Assets177.78 M
Total Current Liabilities19.79 M Total Debt180 K Total Liabilities21.67 M Total Revenue57.37 M
Technical Data
High 52 week126.37 Low 52 week65.41 Last close90.01 Last change-1.7%
RSI53.85 Average true range3.99 Beta1.06 Volume182.38 K
Simple moving average 20 days2.14% Simple moving average 50 days-2.93% Simple moving average 200 days4.69%
Performance Data
Performance Week2.31% Performance Month5.72% Performance Quart-12.74% Performance Half16.94%
Performance Year-14.59% Performance Year-to-date27.08% Volatility daily2.78% Volatility weekly6.21%
Volatility monthly12.73% Volatility yearly44.1% Relative Volume295.56% Average Volume212.25 K
New High0.99% New Low

News

2019-06-14 14:06:11 | Enanta's Respiratory Virus Drug Aces Midstage Study

2019-06-14 11:12:07 | How Much Did Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA CEO Pocket Last Year?

2019-06-14 09:51:28 | UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial

2019-06-14 06:00:00 | Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus RSV

2019-06-10 16:00:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

2019-06-10 08:00:00 | AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

2019-05-30 08:00:00 | AbbVie's MAVIRET™ now listed in New Brunswick

2019-05-15 11:11:03 | Do Enanta Pharmaceuticals's NASDAQ:ENTA Earnings Warrant Your Attention?

2019-05-14 16:01:00 | Enanta Pharmaceuticals to Present at Upcoming Investor Conference

2019-05-08 00:02:11 | Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT

2019-05-07 21:00:10 | Enanta Pharmaceuticals, Inc. ENTA Q2 2019 Earnings Call Transcript

2019-05-07 17:25:09 | Enanta Pharmaceuticals ENTA Beats Q2 Earnings Estimates

2019-05-07 16:16:26 | Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot

2019-05-07 16:00:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019

2019-05-02 14:22:17 | Here’s What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA

2019-04-30 10:32:02 | Analysts Estimate Enanta Pharmaceuticals ENTA to Report a Decline in Earnings: What to Look Out for

2019-04-22 16:30:00 | Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019

2019-04-15 09:40:02 | VKTX or ENTA: What to Expect from Revenue Growth in 2019

2019-04-15 08:05:54 | What Are Analysts Recommending for VKTX and ENTA?

2019-04-11 10:13:00 | Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019

2019-04-11 09:00:00 | AbbVie's MAVIRET™ now reimbursed in Quebec

2019-04-05 15:32:02 | Can You Imagine How Chuffed Enanta Pharmaceuticals's NASDAQ:ENTA Shareholders Feel About Its 216% Share Price Gain?

2019-04-04 10:00:00 | AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

2019-04-01 09:25:01 | The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

2019-03-27 05:24:00 | Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019

2019-03-18 07:30:00 | Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies

2019-03-11 07:30:00 | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

2019-02-15 07:35:00 | Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth

2019-02-06 22:49:54 | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT

2019-02-06 20:43:08 | Enanta Pharmaceuticals Inc ENTA Q1 2019 Earnings Conference Call Transcript

2019-02-06 17:10:10 | Enanta Pharmaceuticals ENTA Lags Q1 Earnings and Revenue Estimates

2019-02-06 16:07:13 | Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot

2019-02-06 16:01:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

2019-01-30 10:31:03 | Enanta Pharmaceuticals ENTA Earnings Expected to Grow: Should You Buy?

2019-01-22 12:09:11 | Do You Like Enanta Pharmaceuticals, Inc. NASDAQ:ENTA At This P/E Ratio?

2019-01-22 08:00:00 | Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018

2019-01-03 08:00:00 | Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference

2018-12-20 08:00:00 | Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-15 11:23:55 | Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc ENTA

2018-12-05 10:28:44 | Is Enanta Pharmaceuticals Inc’s NASDAQ:ENTA CEO Pay Fair?

2018-11-29 16:48:07 | Enanta Pharmaceuticals Inc ENTA Files 10-K for the Fiscal Year Ended on September 30, 2018

2018-11-29 00:11:44 | Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT

2018-11-26 19:34:33 | Enanta Pharmaceuticals Inc ENTA Q4 2018 Earnings Conference Call Transcript

2018-11-26 16:16:57 | Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot

2018-11-26 16:01:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

2018-11-19 10:30:03 | Enanta Pharmaceuticals ENTA Expected to Beat Earnings Estimates: Should You Buy?

2018-11-13 11:40:00 | Enanta Announces that AbbVie’s MAVYRET™ glecaprevir/pibrentasvir Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

2018-11-13 11:30:00 | AbbVie's MAVYRET™ glecaprevir/pibrentasvir Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

2018-11-07 10:10:03 | Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals ENTA

2018-10-29 07:30:00 | Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018